Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs.
OBJECTIVE
To evaluate a [13C]urea breath and blood test (UBBT) for detection of gastric infections with Helicobacter spp in dogs.


METHODS
8 Beagles with, and 3 Beagles without, gastric Helicobacter spp infection.


METHODS
The UBBT was evaluated in dogs of known infection status before and after treatment with amoxicillin, metronidazole, and famotidine (AMF). A standard dose of [13C]urea (4 mg/kg of body weight) was given, and breath and blood samples were obtained at 0, 20, 40, and 60 minutes after administration. Effect of AMF treatment on breath and blood 13CO2 values, gastric urease activity (GUA), and gastric spiral organisms (GSO) was evaluated 3 to 4 and 28 to 29 days after 14 days of AMF treatment.


RESULTS
Breath and blood 13CO2 values were higher in infected dogs than uninfected dogs. Endogenous 13CO2 production was minimal. Breath and blood 13CO2 values varied by 10 and 13%, respectively, between test periods. There was a correlation (R2 = 0.985) between breath and blood 13CO2 values. In 6 of 8 infected dogs, these values were decreased 3 days after completion of AMF administration and biopsy specimens lacked GSO and GUA . For these 6 dogs, breath and blood 13CO2 values were variable 28 days after completion of AMF treatment, and were associated with recurrence of GSO in 6 dogs and GUA in 4 dogs.


CONCLUSIONS
Results of this study indicate that UBBT may provide a noninvasive procedure for detection of gastric infections with Helicobacter spp in dogs. Treatment with amoxicillin, metronidazole, and famotidine may not be effective in eradicating gastric infections with Helicobacter spp in dogs.
Cornetta
A M
AM
Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Simpson
K W
KW
Strauss-Ayali
D
D
McDonough
P L
PL
Gleed
R D
RD
D000658:Amoxicillin / Q000627:therapeutic use; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001706:Biopsy / Q000662:veterinary; D001944:Breath Tests; D002247:Carbon Isotopes; D004283:Dog Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D004285:Dogs; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D015203:Reproducibility of Results; D013047:Specific Pathogen-Free Organisms; D013270:Stomach / Q000201:enzymology / Q000473:pathology; D014508:Urea; D014510:Urease / Q000032:analysis
D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D002247:Carbon Isotopes; D008795:Metronidazole; D015738:Famotidine; D000658:Amoxicillin; D014508:Urea; D014510:Urease